Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing

Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing

Introduction: Genomic alterations in the juxtamembrane exon 14 splice sites in NSCLC lead to increased MET stability and oncogenesis. We present the largest cohort study of MET Exon 14 (METex14) using whole transcriptome sequencing. Methods: A total of 21,582 NSCLC tumor samples underwent complete g...

Full description

Bibliographic Details
Main Authors: So Yeon Kim, MD, Jun Yin, MD, Stephen Bohlman, MD, PhD, Phillip Walker, PhD, Sanja Dacic, MD, PhD, Chul Kim, MD, Hina Khan, MD, Stephen V. Liu, MD, Patrick C. Ma, MD, Misako Nagasaka, MD, PhD, Karen L. Reckamp, MD, Jim Abraham, PhD, Dipesh Uprety, MD, Feng Wang, PhD, Joanne Xiu, PhD, Jian Zhang, PhD, Haiying Cheng, MD, PhD, Balazs Halmos, MD
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:JTO Clinical and Research Reports
Subjects:
METex14
Non–small cell lung cancer
Whole transcriptome sequencing
RNA expression
MDM2
Immune signatures
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364322001059

Internet

http://www.sciencedirect.com/science/article/pii/S2666364322001059

Similar Items